Statin Class Labeling Should Include Liver Failure As Adverse Event - OPDRA
Executive Summary
Class labeling for HMG-CoA reductase inhibitors should be updated to include liver failure as an adverse event, an Office of Postmarketing Drug Risk Assessment safety review concludes.
You may also be interested in...
Pravachol Rx Interaction Profile Is Viewed Favorably In Statins OTC Review
The drug interaction profile of Bristol-Myers Squibb's Pravachol may make the cholesterol-lowering agent a more attractive OTC switch candidate than Merck's Mevacor, members of the statin OTC switch advisory committee suggested.
Pravachol Rx Interaction Profile Is Viewed Favorably In Statins OTC Review
The drug interaction profile of Bristol-Myers Squibb's Pravachol may make the cholesterol-lowering agent a more attractive OTC switch candidate than Merck's Mevacor, members of the statin OTC switch advisory committee suggested.
Novartis Lescol Liver Function Test Requirements Reduced In Revised Label
Novartis' Lescol (fluvastatin) revised labeling reduces the frequency of required liver function tests by eliminating the "periodic" follow-up requirement.